Molecular Medicine Partnership Unit
Co-directors of the MMPU: Andreas Kulozik, University Hospital Heidelberg (left) and Matthias Hentze, EMBL (right).
Click on the image for a larger version
Partners: EMBL Heidelberg; University Hospital Heidelberg - Medical Faculty, Heidelberg
The Molecular Medicine Partnership Unit (MMPU) was established in 2002 as a joint venture of EMBL and the Medical Faculty of the University of Heidelberg. The initial agreement was for a three year pilot phase, and was renewed for another ten years in 2004.
Currently, the MMPU has more than 80 internationally recruited members, divided into eight research groups whose research themes all address common disease entities and include the diseases of childhood and adolescence such as blood disorders and cancers, chronic lung diseases (in particular cystic fibrosis), and “adult disorders” such as defective cholesterol regulation, hemochromatosis and colorectal cancer.
Every MMPU group is co-staffed by EMBL and the Medical Faculty. The directorship of MMPU is shared by Andreas Kulozik from Heidelberg University and Matthias Hentze, EMBL’s Associate Director. The MMPU brings together the expertise of both partners in a complementary manner to bridge the gap between basic and medical research.
The external scientific review in 2008 strongly recommended that a common facility should be provided to house the collaborating groups. This was implemented in September 2011 when the MMPU groups finalised their relocation into the Otto Meyerhof Centre, which is provided by the University of Heidelberg and has available both lab and patient facilities.
The MMPU website could be viewed following either of these links: